Home / Intelligence / Webinars / How to Develop Strong Evidence to Enable Optimal Access Recording
Available On Demand
Communicating a compelling value story to clinicians and payers is key to launching a product successfully and optimizing value throughout the product lifecycle.
- But how exactly does one generate evidence that will educate stakeholders on the disease state, shape the future market and support your value narrative?
- What are the ‘nuts and bolts’ of designing and conducting such studies?
- How do you distill down to the key value messages from a complex data set to be most impactful to clinical and payer audiences?
Learn how Burden of Illness studies are conducted and how this study type could support your disease areas! The Trinity team will highlight the importance of evidence generation through the lens of a scientific Burden of Illness study that we recently conducted with a global pharma company. Beyond the scientific implications of studies of this kind, we will delve into the real-world applications of this evidence from a market access perspective.
Please complete the form to watch our Trinity Webinar: How to Develop Strong Evidence to Enable Optimal Access.
By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.
Related Intelligence
Blog
Rise with the waves: France – Accelerating Pricing and Market Access: Two Policies Shaping Pharma’s Future
Executive Summary The latest publication of new reimbursement regulations in the French Social Security Financing Act (PLFSS 2024), coupled with the recent approval of HEMGENIX® through the direct access scheme in France this past December, underline continued efforts in France to innovate its healthcare system. The 2024 PLFSS emphasizes: The direct access scheme is expected […]
Read More
Webinars
2023 NRDL Update: An Ongoing Voyage of Innovation and Accessibility
May 1, 2024 | 12:00 – 12:45 PM ET / 18:00 – 18:45 CET
An additional session will be offered on May 7th at 16:00-16:45 (UTC+8:00) – Asia/Shanghai How can manufacturers strategize for pricing and market access success amidst the evolving landscape of China’s NRDL? As China continues to be a key pharmaceutical market, understanding the latest National Reimbursement Drug List (NRDL) trends and policy evolvement is crucial for […]
Sign Up Now
White Papers
Evidence Generation in a Post-IRA World
Since the passage of the Inflation Reduction Act (IRA) in 2022, the pharmaceutical industry has significantly altered how they approach and plan for evidence generation activities to best support product launches and pricing and access negotiations. Leading life science companies are taking proactive steps to adjust how and when they develop evidence and how they […]
Read More